TUCSON, Ariz.--(BUSINESS WIRE)--AmpliMed Corporation, a cancer therapeutics company, today announced that data from three clinical trials of Amplimexon® in various cancer types will be presented during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place May 30 to June 3, 2008, at McCormick Place in Chicago. Investigators will present final results from a Phase 1/2 trial of Amplimexon (imexon for injection) in metastatic melanoma, updated data from a Phase 1 trial of Amplimexon in combination with docetaxel (Taxotere) in breast, lung and prostate cancer and updated data from a Phase 1 trial of Amplimexon in combination with gemcitabine (Gemzar®) in advanced pancreatic cancer.
